CA2477573A1 - Headloop dna amplification - Google Patents
Headloop dna amplification Download PDFInfo
- Publication number
- CA2477573A1 CA2477573A1 CA002477573A CA2477573A CA2477573A1 CA 2477573 A1 CA2477573 A1 CA 2477573A1 CA 002477573 A CA002477573 A CA 002477573A CA 2477573 A CA2477573 A CA 2477573A CA 2477573 A1 CA2477573 A1 CA 2477573A1
- Authority
- CA
- Canada
- Prior art keywords
- nucleic acid
- primer
- region
- amplification
- target
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000004544 DNA amplification Effects 0.000 title 1
- 230000003321 amplification Effects 0.000 claims abstract description 83
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 83
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 79
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 76
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 76
- 238000000034 method Methods 0.000 claims abstract description 73
- 108091093088 Amplicon Proteins 0.000 claims abstract description 22
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 9
- 108020004414 DNA Proteins 0.000 claims description 76
- 230000037452 priming Effects 0.000 claims description 25
- 241000894007 species Species 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 18
- 230000002441 reversible effect Effects 0.000 claims description 17
- 238000003556 assay Methods 0.000 claims description 16
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 15
- 239000002773 nucleotide Substances 0.000 claims description 13
- 125000003729 nucleotide group Chemical group 0.000 claims description 13
- 108010070675 Glutathione transferase Proteins 0.000 claims description 12
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 11
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 238000000137 annealing Methods 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 230000001105 regulatory effect Effects 0.000 claims description 8
- 108091029430 CpG site Proteins 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 230000002159 abnormal effect Effects 0.000 claims description 7
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims description 7
- 229940104302 cytosine Drugs 0.000 claims description 7
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 6
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims description 6
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 6
- 229960003237 betaine Drugs 0.000 claims description 6
- 238000007385 chemical modification Methods 0.000 claims description 6
- 230000004048 modification Effects 0.000 claims description 6
- 238000012986 modification Methods 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 5
- 230000011987 methylation Effects 0.000 claims description 5
- 238000007069 methylation reaction Methods 0.000 claims description 5
- 101150082998 pi gene Proteins 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 230000035772 mutation Effects 0.000 claims description 3
- 229940035893 uracil Drugs 0.000 claims description 3
- 108020004465 16S ribosomal RNA Proteins 0.000 claims description 2
- 229930024421 Adenine Natural products 0.000 claims description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 2
- 241000196324 Embryophyta Species 0.000 claims description 2
- 229960000643 adenine Drugs 0.000 claims description 2
- 101150008380 gstp1 gene Proteins 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 239000000376 reactant Substances 0.000 claims description 2
- 238000003753 real-time PCR Methods 0.000 claims description 2
- 230000030933 DNA methylation on cytosine Effects 0.000 claims 1
- 238000009004 PCR Kit Methods 0.000 claims 1
- 101001032469 Xenopus laevis Glutathione S-transferase P 1 Proteins 0.000 claims 1
- 108091036078 conserved sequence Proteins 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 108020004418 ribosomal RNA Proteins 0.000 claims 1
- 239000013615 primer Substances 0.000 description 154
- 239000012634 fragment Substances 0.000 description 35
- 238000006243 chemical reaction Methods 0.000 description 31
- 239000013612 plasmid Substances 0.000 description 18
- 230000000295 complement effect Effects 0.000 description 10
- 238000002844 melting Methods 0.000 description 9
- 230000008018 melting Effects 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 238000012408 PCR amplification Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 102220510114 Phospholipid scramblase 3_F52A_mutation Human genes 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- 230000001351 cycling effect Effects 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 239000000155 melt Substances 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 210000003705 ribosome Anatomy 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101000617823 Homo sapiens Solute carrier organic anion transporter family member 6A1 Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000013211 curve analysis Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 102000001718 human gonad-specific transporter Human genes 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 108700022487 rRNA Genes Proteins 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical group [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 2
- 239000010902 straw Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 2
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical group C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- 241000478814 Acidops Species 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102100036263 Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Human genes 0.000 description 1
- 101150018047 HBAD gene Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108010025076 Holoenzymes Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001001786 Homo sapiens Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Proteins 0.000 description 1
- 101150017040 I gene Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 241000272168 Laridae Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- -1 Mg2+ ions Chemical class 0.000 description 1
- 101100449758 Onchocerca volvulus GST1 gene Proteins 0.000 description 1
- 241001603151 Philus Species 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000521591 Sulfobacillus acidophilus Species 0.000 description 1
- 108700025695 Suppressor Genes Proteins 0.000 description 1
- 241000205180 Thermococcus litoralis Species 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000006203 ethylation Effects 0.000 description 1
- 238000006200 ethylation reaction Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000004890 malting Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000011880 melting curve analysis Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 208000033937 musculocontractural type Ehlers-Danlos syndrome Diseases 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000012985 polymerization agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPS0768A AUPS076802A0 (en) | 2002-02-26 | 2002-02-26 | Selective nucleic acid amplification |
| AUPS0768 | 2002-02-26 | ||
| PCT/AU2003/000244 WO2003072810A1 (en) | 2002-02-26 | 2003-02-26 | Headloop dna amplification |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2477573A1 true CA2477573A1 (en) | 2003-09-04 |
Family
ID=3834367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002477573A Abandoned CA2477573A1 (en) | 2002-02-26 | 2003-02-26 | Headloop dna amplification |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7618773B2 (https=) |
| EP (1) | EP1483406A4 (https=) |
| JP (1) | JP4417723B2 (https=) |
| CN (1) | CN100516234C (https=) |
| AU (1) | AUPS076802A0 (https=) |
| CA (1) | CA2477573A1 (https=) |
| WO (1) | WO2003072810A1 (https=) |
| ZA (1) | ZA200407147B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE554187T1 (de) * | 2007-03-08 | 2012-05-15 | Idaho Technology | Verfahren für die schmelzanalyse der nukleinsäuren |
| EP2167964B1 (de) * | 2007-06-13 | 2015-03-11 | Attomol GmbH Molekulare Diagnostika | Verfahren zur durchführung und auswertung von mix&measure assays für die messung von reaktionskinetiken sowie von konzentrationen und affinitäten von analyten im multiplexformat |
| EP2071035A1 (en) | 2007-12-13 | 2009-06-17 | Epigenomics AG | Facilitator and method for amplification |
| AU2011224534B2 (en) | 2010-03-08 | 2014-10-09 | Dana-Farber Cancer Institute, Inc. | Full COLD-PCR enrichment with reference blocking sequence |
| EP2691541B1 (en) | 2011-03-31 | 2017-10-18 | Dana-Farber Cancer Institute, Inc. | Method for enriching in single-stranded mutant sequences from mixture of wild-type and mutant sequences |
| US20140106354A1 (en) | 2011-04-18 | 2014-04-17 | Garvan Institute Of Medical Research | Method of Diagnosing Cancer |
| WO2012162621A1 (en) | 2011-05-26 | 2012-11-29 | Brandeis University | Methods for suppression pcr |
| US20140322717A1 (en) * | 2011-11-18 | 2014-10-30 | The Trustees Of Columbia University In The City Of New York | Selective amplification and detection of mutant gene alleles |
| US9133490B2 (en) | 2012-05-16 | 2015-09-15 | Transgenomic, Inc. | Step-up method for COLD-PCR enrichment |
| EP3194624B1 (en) | 2014-09-15 | 2022-02-16 | Garvan Institute of Medical Research | Methods for diagnosis, prognosis and monitoring of breast cancer and reagents therefor |
| CN104845967B (zh) * | 2015-04-15 | 2020-12-11 | 苏州新海生物科技股份有限公司 | 寡聚核苷酸片段及使用其的选择性扩增目标核酸序列变异体的方法及应用 |
| WO2018111835A1 (en) | 2016-12-12 | 2018-06-21 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for molecular barcoding of dna molecules prior to mutation enrichment and/or mutation detection |
| WO2018209092A1 (en) | 2017-05-10 | 2018-11-15 | Board Of Regents, The University Of Texas System | Methods and devices related to amplifying nucleic acid at a variety of temperatures |
| US11174511B2 (en) | 2017-07-24 | 2021-11-16 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for selecting and amplifying DNA targets in a single reaction mixture |
| US10513730B2 (en) * | 2017-11-22 | 2019-12-24 | Safeguard Biosystems Holdings Ltd. | Asymmetric PCR methods, primers and kits |
| EP3599283A1 (en) * | 2018-07-25 | 2020-01-29 | Blue DNA Companion | Method for assessing fecal pollution in water |
| CN110283913A (zh) * | 2019-07-21 | 2019-09-27 | 广州奥百阕谱生物科技有限公司 | Rassf1a基因甲基化状态检测试剂盒及其应用 |
| CN110607369A (zh) * | 2019-09-24 | 2019-12-24 | 广州奥百阕谱生物科技有限公司 | Septin9基因甲基化状态检测试剂盒及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5565340A (en) * | 1995-01-27 | 1996-10-15 | Clontech Laboratories, Inc. | Method for suppressing DNA fragment amplification during PCR |
| AUPP312998A0 (en) * | 1998-04-23 | 1998-05-14 | Commonwealth Scientific And Industrial Research Organisation | Diagnostic assay |
| GB9812768D0 (en) * | 1998-06-13 | 1998-08-12 | Zeneca Ltd | Methods |
-
2002
- 2002-02-26 AU AUPS0768A patent/AUPS076802A0/en not_active Abandoned
-
2003
- 2003-02-26 WO PCT/AU2003/000244 patent/WO2003072810A1/en not_active Ceased
- 2003-02-26 US US10/505,779 patent/US7618773B2/en not_active Expired - Fee Related
- 2003-02-26 CN CNB03809391XA patent/CN100516234C/zh not_active Expired - Fee Related
- 2003-02-26 EP EP03707898A patent/EP1483406A4/en not_active Withdrawn
- 2003-02-26 JP JP2003571490A patent/JP4417723B2/ja not_active Expired - Fee Related
- 2003-02-26 CA CA002477573A patent/CA2477573A1/en not_active Abandoned
-
2004
- 2004-09-07 ZA ZA200407147A patent/ZA200407147B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003072810A1 (en) | 2003-09-04 |
| US7618773B2 (en) | 2009-11-17 |
| AUPS076802A0 (en) | 2002-03-21 |
| JP2005518217A (ja) | 2005-06-23 |
| JP4417723B2 (ja) | 2010-02-17 |
| EP1483406A4 (en) | 2007-10-24 |
| EP1483406A1 (en) | 2004-12-08 |
| US20050221312A1 (en) | 2005-10-06 |
| CN1650029A (zh) | 2005-08-03 |
| CN100516234C (zh) | 2009-07-22 |
| ZA200407147B (en) | 2006-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2477573A1 (en) | Headloop dna amplification | |
| US5849497A (en) | Specific inhibition of the polymerase chain reaction using a non-extendable oligonucleotide blocker | |
| US8455197B2 (en) | Nucleic acid amplification | |
| EP2606148B1 (en) | Helicase dependent isothermal amplification using nicking enzymes | |
| US20120021930A1 (en) | Multiplex Nucleic Acid Detection | |
| US20080044812A1 (en) | Melting Temperature Dependent Dna Amplification | |
| US20080044921A1 (en) | Primers used in novel gene amplification method | |
| US20240076633A1 (en) | Pcr buffer composition for increasing activity of dna polymerase with increased gene mutation specificity | |
| WO2018042598A1 (ja) | ジカウイルス検出用プライマーセット | |
| TR201815755T4 (tr) | Allele özgü reaktif primer kullanan nükleik asit amplifikasyon yöntemi. | |
| JP6964900B2 (ja) | 核酸増幅の特異的抑制方法 | |
| US20140377762A1 (en) | Method for enriching and detection of variant target nucleic acids | |
| CA2579918A1 (en) | Nucleic acid detection method involving the direct generation of a measurable signal | |
| JP2008029335A (ja) | 新規遺伝子増幅法に用いられるプライマーセットおよびキット | |
| AU2003212087B2 (en) | Headloop DNA amplification | |
| US9074248B1 (en) | Primers for helicase dependent amplification and their methods of use | |
| EP2505670B1 (en) | Method for the identification of SNPs | |
| JP5417752B2 (ja) | 高精度の標的核酸の検出方法および標的核酸検出用キット | |
| JP4942160B2 (ja) | ＲｅｃＡタンパク質を利用した核酸の等温増幅法 | |
| AU2003209812B2 (en) | Melting temperature dependent DNA amplification | |
| JPWO2006070666A1 (ja) | 遺伝子多型の同時検出方法 | |
| EP1903117A1 (en) | Methods for the detection of mutations by means of primers that hybridize contiguously | |
| JP2008161164A (ja) | 人工ミスマッチ核酸を含むプライマーを用いた遺伝子検出法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |